|Mr. Richard W. Pascoe||CEO, CFO, Sec., Principal Accounting Officer & Director||500.23k||N/A||1964|
|Mr. Brian T. Dorsey||Sr. VP & Chief Devel. Officer||331.89k||N/A||1969|
|Mr. Neil C. Morton||Sr. VP & Chief Bus. Officer||286.81k||N/A||1976|
|Ms. Kelly Deck||Exec. Director of Fin.||N/A||N/A||N/A|
|Ms. Mary Naggs||VP & Gen. Counsel||N/A||N/A||N/A|
Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology. The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma. It has a license and stock issuance agreement with Forendo Pharma Ltd. to develop and commercialize fispemifene, a tissue-specific selective estrogen receptor modulator to treat symptomatic secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men. Apricus Biosciences, Inc. operates in Europe, Canada, Latin America, and the Asia Pacific. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.
Apricus Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.